Patients and follow-up years per cohort | Events per cohort | Comparison | ||||||
Cohort | Patients | Total years | Mean±sd years# | Events | IR per patient-year | IR difference (95% CI) | IR ratio (95% CI) | |
Exacerbation (primary outcome) | TT | 1181 | 1022 | 0.74±0.88 | 812 | 0.794 | −0.119 (−0.233– −0.004) | 0.870 (0.763–0.994) |
DB | 466 | 346 | 0.87±1.04 | 316 | 0.913 | |||
Acute respiratory event (secondary outcome) | TT | 1181 | 592 | 0.37±0.53 | 957 | 1.618 | −0.560 (−0.803– −0.316) | 0.743 (0.659–0.840) |
DB | 466 | 172 | 0.50±0.73 | 374 | 2.178 | |||
Treatment failure (secondary outcome) | TT | 1181 | 867 | 0.60±0.77 | 874 | 1.008 | −0.227 (−0.374– −0.080) | 0.816 (0.720–0.927) |
DB | 466 | 278 | 0.73±0.92 | 343 | 1.236 | |||
Acute OCS course (secondary outcome) | TT | 1181 | 1367 | 1.02±1.21 | 683 | 0.499 | −0.058 (−0.134–0.019) | 0.896 (0.777–1.037) |
DB | 466 | 477 | 1.16±1.28 | 266 | 0.557 | |||
Antibiotics course (secondary outcome) | TT | 1181 | 1341 | 1.00±1.17 | 659 | 0.491 | −0.052 (−0.129–0.025) | 0.904 (0.781–1.049) |
DB | 466 | 465 | 1.14±1.27 | 253 | 0.544 | |||
Pneumonia diagnosis (secondary outcome) | TT | 1181 | 2772 | 2.24±2.16 | 62 | 0.022 | −0.003 (−0.014–0.009) | 0.899 (0.560–1.480) |
DB | 466 | 1044 | 2.35±2.00 | 26 | 0.025 |
OCS: oral corticosteroid; TT: triple therapy; DB: dual bronchodilation with long-acting muscarinic antagonist/long-acting inhaled β-agonist. #: mean follow-up time in years available.